The use of prostate specific antigen for prostate cancer screening : a managed care perspective.
Detection and treatment of early stage prostate cancer. Seminar. USA, 1993/12.
A large nonprofit staff model Health Maintenance Organization experienced increased use of prostate specific antigen (PSA) as a screening test for prostate cancer beginning in May 1991.
A critical evaluation of the evidence in support of PSA screening was done and concluded that the use of PSA to screen for prostate cancer did not meet the criteria for an effective screening program.
A guideline stating that PSA was not recommended as a screening test was implemented focusing on a model of shared decision making.
PSA test ordering decreased significantly when patients were fully informed about the evidence for PSA screening.
If PSA screening had continued at the peak rate, the cascade of intervention initiated by screening would have resulted in significant complications and approximately $4,800,000 in increased costs.
Mots-clés Pascal : Epithélioma, Prostate, Antigène spécifique tumeur, Etats Unis, Amérique du Nord, Amérique, Dépistage, Exploration, Homme, Mâle, Appareil urinaire pathologie, Prostate pathologie, Appareil génital mâle pathologie, Tumeur maligne, Exploration immunologique
Mots-clés Pascal anglais : Carcinoma, Prostate, Tumor specific antigen, United States, North America, America, Medical screening, Exploration, Human, Male, Urinary system disease, Prostate disease, Male genital diseases, Malignant tumor, Immunological investigation
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0217759
Code Inist : 002B14D02. Création : 09/06/1995.